Artemisinin-naphthoquine combination (ARCO®): An overview of the progress

Pharmaceuticals

Volumn 3, Issue 12, 2010, Pages 3581-3593

  Hombhanje, Francis W ^a   Huang, Qingyun ^b  

^a Divine Word University   (Papua New Guinea)

^b Kunming Pharma   (China)

Author keywords

ARCO; Artemisinin; Artemisinin naphthoquine combination; Naphthoquine; Plasmodium falciparum

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ARCO; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ PLUS NAPHTHOQUINE; CHLOROQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; PYRIMETHAMINE PLUS SULFADOXINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; COMBINATION CHEMOTHERAPY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; HEADACHE; HUMAN; MALARIA FALCIPARUM; NAUSEA; PATIENT SATISFACTION; PLASMODIUM VIVAX MALARIA; REVIEW; SINGLE DRUG DOSE; VOMITING;

EID: 78651232657     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3123581     Document Type: Review

References (44)

1. Hastings, I.M.; Watkins, W.M.; White, N.J. The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2002, 357, 505-519.
2. Arav-Boger, R.; Shapiro, T.A. Molecular mechanisms of resistance in antimalarial chemotherapy: the unmet challenge. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 565-585.
3. Hastings, I.M.; Watkins, W.M. Tolerance is the key to understanding antimalarial drug resistance. Trends Parasitol. 2006, 22, 71-77.
4. Na Bangchang, K.; Ruengweerayut, R.; Mahamad, P.; Ruengweerayut, K.; Chaijaroenkul, W. Declining efficacy of a three-day combination regimen of mefloquine-artesunate in a multi-drug resistance area along Thai-Myanmar border. Malar. J. 2010, 9, 273-282.
5. Choi, S.R.; Mukherjee, P.; Avery, M.A. The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr. Med. Chem. 2008, 15, 161-171.
6. White, N.J.; Ho, M. The pathophysiology of malaria. Adv. Parasitol. 1992, 31, 83-173.
7. Maitland, K.; Marsh, K. Pathophysiology of severe malaria in children. Acta Tropica 2003, 90, 131-140.
8. Dondorp, A.M. Pathophysiology, clinical presentation and treatment of cerebral malaria. Neurol. Asia. 2005, 10, 67-77.
9. White, N.J. Assessment of the pharmacodynamic properties of antimalarial drug in-vivo. Antimicrobial. Agents Chemother. 1997, 41, 1413-1422.
10. Qinghaosu: Antimalarial Coordinating Research Group. Antimalarial studies on Qinghaosu. Chin. Med. J. 1979, 92, 811-816.
11. Jiang, J.B.; Li, G.Q.; Guo, X.B.; Kong, Y.C.; Arnold, K. Antimalarial activity of mefloquine and Qinghaosu. Lancet 1982, 320, 285-288.
12. White, N.J. Clinical pharmacokinetics and pharmacodynamics of artemisinin and its derivatives. Trans. R. Soc. Trop. Med. Hyg. 1994, 88 (Suppl. 1), S41-S43.
13. Li, G.Q.; Guo, X.B.; Fu, L.C.; Jian, H.X.; Wang, X.H. Clinical trials of artemisinin and its derivatives in the treatment of malaria in China. Trans. R. Soc. Trop. Med. Hyg. 1994, 88 (Suppl. 1), S5-S6.
14. Wang, J.Y.; Shan, C.Q.; Fu, D.D.; Sun, Z.W.; Ding, D.B. Efficacy of naphthoquine, artemisinine and a combination of the two drugs in the treatment of f alciparum malaria. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2003, 21, 131-133.
15. Wang, J.Y.; Cao, W.C.; Shan, C.Q; Zhang, M.; Li, G.F.; Ding, D.B.; Shi, Y.L.; Wu B.A. Naphthoquine phosphate and its combination with artemisinin. Acta Tropica 2004, 89, 375-381.
16. Wang, J.Y.; Ding, D.B.; Li G.F.; Zhao, J.H. Therapeutic efficacy of naphthoquine phosphate combined with artemisinine against Plasmodium knowlesi. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2008, 26, 442-444.
17. Tun, T.; Tint, H.S.; Lin, K.; Kyaw, T.T.; Myunt, M.K.; Khaing, W.; Tun, Z.U. Efficacy of oral single dose therapy with artemisinin-naphthoquine phosphate in uncomplicated falciparum malaria. Acta Tropica 2009, 111, 275-278.
18. Toure, O.A.; Penali, L.K.; Yapi, J.; Ako, B.A.; Toure, W.; Djerea, K.; Gomez, G.O.; Makaila, O.A. Comparative, randomized clinical trial of artemisinin/naphthoquine twice daily one day versus artemether/lumefantrine six doses regimen in children and adults with uncomplicated falciparum malaria in Cote d'Ivoire. Malar. J. 2009, 8, 148-158.
19. Hombhanje, F.W.; Linge, D.; Saweri, A.; Kuanch, C.; Jones, R.; Toraso, S.; Geita, J.; Masta, A.; Kevau, I.; Hiawalyer, G.; Sapuri, M. Artemisinin-naphthoquine combination (ARCO™) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy. Malar. J. 2009, 8, 196-304.
20. Klayman, D.L. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985, 228, 1049-1055.
21. Ye, L.; Xu, G.; Wang, R.; Li, J.; Zhu, C.; Tang, S.; Sun, Y. Hundred and one cases of Plasmodium falciparum patients treated with naphthoquine phosphate (in Chinese). Chin. J. Parasitol. Parasitic. Dis. 1999, 17, 20-23.
22. Kuhn, T.; Wang, Y. Artemisinin-an innovative cornerstone for anti-malaria therapy. Prog. Drug. Res. 2008, 66, 385-422.
23. Guo, W.; Guo, X.; Zheng, Q.; Tan, B.; Chen, R.; Ou, F.; Fu, L. A randomized-control study of naphthoquine and artesunate in the treatment of falciparum malaria. J. Guangzhou Uni. Trad. Chin. Med. 2000, 17, 235-237.
24. Cui, L.; Su, X.Z. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev. Anti-Infect. Ther. 2009, 7, 999-1013.
25. Medhi, B.; Patyar, S.; Rao, R.S.; Byrav, P.D.S.; Prakash, A. Pharmacokinetic and toxicological profile of artemisinin compounds: an update. Pharmacology 2009, 84, 323-332.
26. Qu, H.Y.; Gao, H.Z.; Hao, G.T.; Li, Y.Y.; Li, H.Y.; Hu, J.C.; Wang, X.F.; Liu, W.L.; Liu, Z.Y. Single-Dose safety, pharmacokinetics, and food effects studies of compound naphthoquine phosphate tablets in healthy volunteers. J. Clin. Pharmacol. 2010, doi: 10.1177/0091270009356296.
27. Wang, J.; Huang, L.; Li, J.; Fan, Q.; Long, Y.; Li, Y.; Zhou, B. Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS One 2010, 5, e9582.
28. Giao, P.T.; de Vries, P.J. Pharmacokinetic interactions of antimalarial agents. Clin. Pharmacokinet. 2001, 40, 343-373.
29. Martinelli, A.; Moreira, R.; Ravo, P.V. Malaria combination therapies: advantages and shortcomings. Mini Rev. Med. Chem. 2008, 8, 201-212.
30. World Health Organization. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria; WHO: Geneva, Switzerland, 2003.
31. nd ed.; WHO: Geneva, Switzerland, 2003; Whqlibdoc.who.int/publications2010/9789241547925_eng.pdf/, accessed on 14 December 2010.
32. World Health Organization. Antimalarial drug combination therapy. Report of a WHO Technical Consultation (WHO/CDS/RBM/2001.35); WHO: Geneva, Switzerland, 2001.
33. Lefevre, G.; Looareesuwan, S.; Treeprasertsuk, S.; Krudsood, S.; Silachamroon, U.; Gathmann, I.; Mull, R.; Bakshi, R. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug resistant Plasmodium falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. 2001, 64, 247-256.
34. Krudsood, S.; Chalermrut, K.; Pengruksa, C.; Srivilairit, S.; Silachamroon, U.; Treeprasetsuk, S.; Kano, S.; et al. Comparative clinical trial of two-fixed combinations of dihydroartemisinin- naphthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand. Southeast Asian J. Trop. Med. Public. Health 2003, 34, 316-321.
35. van den Broek, I.; Kitx, C.; Al Atas, S.; Libama, F.; Balasegaram, M.; Guthmann, J.-P. Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo. Malar. J. 2006, 5, 113-116.
36. Kokwaro, G.; Mwai, L.; Nzila, A. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Exp. Opi. Pharmacother. 2007, 8, 75-94.
37. ®) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 2005, 99, 459-467.
38. ®) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults. Malar. J. 2006, 5, 73-80.
39. Jackson, Y.; Chappuis, F.; Loutan, L.; Taylor, W. Malaria treatment failures after artemisinin- based therapy in three expatriates: could improved manufacturer information help to decrease the risk of treatment failure? Malar. J. 2006, 5, 81-85.
40. Wasunna, W.; Zurovac, D.; Goodman, C.A.; Robert, W.; Snow, R.W. Why don't health workers prescribe ACT? A qualitative study of factors affecting the prescription of artemether- lumefantrine. Malar. J. 2008, 7, 29-37.
41. Price, R.N.; Nosten, F.; Luxemburger, C.; ter Kuile, F.O.; Paiphun, L.; Price, R.N.; Chongsuphajaisiddhi, T.; White, N.J. Effects of artemisinin derivatives on malaria transmissibility. Lancet 1996, 347, 1654-1658.
42. Okell, L.C.; Drakeley, C.J.; Ghani, A.C.; Bousema, T.; Sutherland, C.J. Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials. Malar. J. 2008, 7, 125-137.
43. Barnes, K.I.; Chanda, P.; Barnabas, G. Impact of large-scale deployment of artemether-lumefantrine on the malaria disease burden in Africa: case study of South Africa, Zambia and Ethiopia. Malar. J. 2009, 8 (suppl. 1), S8.
44. Qigui, L.; Weina, P.J. Severe Embryotoxicity of artemisinin derivatives in experimental animals, but possibly safe in pregnant women. Molecules 2010, 15, 40-57.